Updates from the BRUIN study - long-term safety of pirtobrutinib in R/R MCL 

Wojciech Jurczak, MD, PhD, Jagiellonian University, Krakow, Poland shares updates from the BRUIN Phase I/II trial (NCT03740529) investigating the non-covalent third-generation Bruton’s tyrosine kinase (BTK) inhibitor pirtobrutinib in the treatment of relapsed/refractory (R/R) B-cell malignancies including mantle cell lymphoma. Pirtobrutinib was well-tolerated in terms of hematological toxicity and infections, and the adverse event rate was lower than that seen for second-generation BTK inhibitors. Prof. Jurczak also briefly discusses other trials investigating BTK inhibitors including zanubrutinib and acalabrutinib. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.